GRIN2B and Alzheimer disease: Specifically, “VEGFA–GRIN2B” was 37.8% in AD versus 39.5% in the cognitively normal group, “VEGFA–SIRPA” was 10.2% versus 10.7% (AD vs. cognitive normal), and “VEGFA–EGFR” was 10.2% versus 9.5% (AD vs. cognitive normal).